An analysis of 19 double-blind, randomized, controlled trials showed linagliptin did not increase the risk of cardiovascular events and mortality in type 2 diabetes patients. Data showed cardiovascular events occurred at a rate of 60 among those who took once-daily linagliptin compared with 62 in those who took non-linagliptin medications. The results were presented at the ADA 73rd Scientific Sessions.

Related Summaries